Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alright FDMF investors who are still in this POS. By my estimation the company should only have about 1 million O/S now which means it’ll be difficult to trade. Very weird that the company just changed their name too. OTC MARKETS website has the ticker up & current as FDMFD now. Let’s see if Kistler can drop an update from his Twitter account at all today or this week. Maybe he’s planning to sell off the company or merge it since there aren’t any shares left. Guess we will have to wait and see. OTC is a crazy place and weirder things have happened. Stay positive and try to get out of your positions intelligently. As for me, I’m going to see what old Cap’n Dippy has up his sleeves. I wish you all a positive path out of this mess. Be smart, be aggressive, and good luck.
VIZC looks to be connected to Tomorrow.io in very big and legit ways. If you’re getting loaded or thinking of buying in, now is probably the best time. This one is going to smash 100-200 million volume traded today. If the connection is true, with its O/S & Float, this one can run well above $.50 IMHO
Better load it now IMO
Pink Current. Bye bye. Tried to tell you all, something BIG is coming…
Here’s the problem with you all over-analyzing CZNI and why what you’re all saying doesn’t mean Jack shit. Who cares if a filing came out? What matters is, can you all understand what is in the filing? Fact of the matter is the O/S is maxed out at 3.77 Billion. The CEO set the A/S low and at 3 Billion for a reason. It’s called paying for everything that is needed to accomplish the end goal. And that is getting the company to Pink Current and then getting the Reverse Merger/Merger/Acquisition finalized. It is going to happen. Buying on the Bid or Ask where it is now soon will not matter. When catalysts come pouring in investors will wish they would’ve bought while this sat so low. It is literally a steal at these prices. This stock is going to run over $.04
Mark my words, you don’t load now you’ll be kicking yourselves soon enough in July-August. Make no mistake, it’s going to happen. Smart investors are already loading the boat. Know what you own and be confident in what you already know to be true. The O/S is light and this stock is going to soar and you will only get a very limited time now to buy up as many shares as you can to invest in what will be a life-changing move on this ticker.
Mark this message. I’m telling you now rather than coming back later and telling you “I told you so.” Listen to the idiots who don’t have a clue or listen to a seasoned trader that has made huge predictions (95% which have come to fruition), Conrad Huss is no bum and when this goes he’ll only build upon his already stellar reputation.
Hope you’re smart enough to make the right decision.
$RDAR - this one is set to go off!! Big buys, volume way up over 10-day average and news for the new RAADR Parental 2.0 app is going to drop any time now. Better load up, this one is going up towards a penny again!!
DRNG - next one to go off
I called this one from $.0001-$.0002 and said it would hit $.10, very close & not bad off a chart reading back in November/December.
Thought I’d share the next major runner about to go nuts.
$DRNG - Drone Guarder Inc.
CEO - Adam Taylor (is the ??)
He connects DRNG ?? MAPS MADE EASY ?? DJI (Frank Wang)
Adam Taylor - CEO of DRNG, & Enterprise Sales @ Maps Made Easy & Drones Made Easy. Check Twitter for Maps Made Easy. You can see recent tweets connecting MAPS MADE EASY with DJI & APPLE.
Frank Wang has net worth of $4.6 Billion
Largest drone company in the world.
DJI had their drones used in Game Of Thrones (GOT) & The new Star Wars movies. His drone was also landed on top of the Japanese Prime Minister’s place & their drone was also landed on the White House Lawn. DJI has the newest & most sought after Technology for drones next to Skydio (who also worked with DRNG in the past and still works with them in San Francisco, California.
DJI website:
https://www.dji.com/mobile
Check this out!!! ??
DJI FPV drone video
https://www.dji.com/mobile/dji-fpv?from-google&gclid=Cj0KCQjwk4yGBhDQARIsACGfAetpxRUqwPcIvMy4nFbZ82YxcATwdmF_pObHEufG0h9Zcr4vWpoe3sAaAj-FEALw_wcB
Skydio:
https://www.skydio.com/
DRNG has never done a Reverse Split plus they did one Forward Split and the stock has hit as high as $1.26!!!! With no split. Insanely low O/S & good Float.
DRNG is drone security/protection just like $DPLS.
DRNG is the next big one to take off along with $DGTW
MY STRONG SUGGESTION…load DRNG & DGTW as if you could buy DPLS back at these prices. Both are going to explode very, very soon.
Have a nice day.
DRNG connected to DJI still and possibly Skydio.
Adam Taylor - CEO of DRNG is head of Enterprise Sales at Maps Made Easy. Go check Maps Made Easy Twitter account. They are working with DJI & Apple. Look at past couple of months. They’re still linked together!!! DRNG is going to rocket up now. Better be buying it or else watch the train leave the station.
CZNI - DO NOT SELL OR PANIC SELL. Huge players in on this one. Yield sign is coming off as early as tonight. Filings coming and most likely news of a merger-acquisition. CEO - Conrad Huss has a solid track record of making big runs for stocks. This is the next one. $.0020’s ain’t gonna be shit. Hold strong but don’t hold forever. And don’t sell huge amounts into the Bid or Ask. Let it run organically and take profits along the way. Be smart but help it run high. We don’t need any rookies messing with the run. Be smart people. This one could easily get 300% in a single day.
Remember:
Yield sign coming off, Pink Current
Then good news should drop, possibly MERGER/ACQUISITION News!
O/S and Float allow it to run towards $.01 & possibly higher, easily
BE SMART!
USEI about to run. Better hit that Ask at $.0017 & $.0018. It’s gonna run. Hit bottom of $.0014 already with 100 million purchased like last time. Reversal in effect. Don’t miss this run. Last one it went to $.0070, it’s coming!!! Power Hour.
I hope you all are ready for this one to go sky high. PropTech is going to be big plus they’re getting into Blockchain in the Real Estate sector. Everyone is going to be chasing this wonder after they become Pink Current and the new website comes up. I expect a merger/acquisition deal to happen with them this time around. Could be wrong but that’s what I see happening.
Better buckle up. We are about to start the show.
Also, here’s some good info to look over.
$MSPC - Metrospaces
This is a stock currently priced @ $.0010
It is joining the PropTech Industry which is expecting drastic growth in the Real Estate/Business/Residential property sector. There is not another penny stock priced in this range that can compete with this stock IMO.
Metrospaces - Information
https://www.globenewswire.com/en/news-release/2021/05/19/2232677/0/en/Metrospaces-Announces-Refocusing-of-Business-Plan-to-Become-a-Prop-Tech-Company.html
https://finance.yahoo.com/news/shokworks-powers-state-art-platforms-134500745.html
Letter to Shareholders
https://finance.yahoo.com/news/metrospaces-issues-may-2021-shareholder-141500430.html
Here’s why PropTech is going to drastically increase going forward.
https://www.forbes.com/sites/angelicakrystledonati/2021/01/10/proptech-and-contech-vcs-predict-what-is-in-store-for-2021/
https://www.fool.com/millionacres/real-estate-investing/articles/proptech-investment-dropped-in-2020-will-it-rise-in-2021/
https://techcrunch.com/2021/03/24/10-proptech-investors-see-better-era-for-residential-and-retail-after-pandemic/
MSPC is strongly connected to Shokworks, Shokworks is strongly connected to Rivals Media Group
Rivals Media Group develops sports Apps and created an app with Tampa Bay Buccaneers’s coach, Bruce Arians. The company is also connected with the Raiders and Steelers.
Arians on his Facebook page talking about Rivals Media
https://fb.watch/5NrenhUNre/
Press Release
https://www.businesswire.com/news/home/20201214005042/en/Shokworks-and-Rivals-Media-Partner-to-Create-Second-Screen-Game-to-Benefit-Celebrity-Sports-Foundations
https://arians-app.rivalsmedia.com/
MSPC - Shokworks - Rivals Media
MSPC may have finally made the leaps they’ve been talking about since September 2018. Now is the time because this could be another unicorn.
All my opinion but people kept asking for facts, links, info well now you have enough to get your feet well. Plus you all noticed the 50 million buy which made all of us go, “somebody knows something.” This may be special.
You wanted the next possible Unicorn stock, well this is probably it.
SEC about to suspend NNRX. No filings in over a year. Wave bye bye, it’s coming.
EEGI
NNRX
FDMF
TAWNF
All about to get suspended by SEC. Warning you all in short advance. It’s coming.
Be ready for AFOM to make a move soon. Thus far it hasn’t been able to clear $.0052 & who knows if, when, or how high this will go. One thing is for sure. Last known, AFOM was effected majorly by Covid-19 and experienced quite a setback in movie productions. They are still said to be contracted with Netflix to complete 19 more movies over the next 4 years, which is about 5 movies per year. They still seem to have the relationship with Jeff Deverett & Carmel Valley Productions. Vaccine rollout is on a crazy pace and the country & world are beginning to open up, even with the COVID variants present. As movie theaters, restaurants, and concert venues open up more & more, AFOM has a greater probability of ramping up its business. Also, there’s less than 50 days to go until June 30 SEC deadline to catch up on filings. We all know how this works. If we anticipate something happening and happening rapidly, then we should expect a movie entertainment stock to move briskly. I expect this stock to make a run similarly to RGBP & INND. Both stocks cleared $.08 & I expect AFOM to have a great run with an O/S right at about 4.0 Billion. This one can run when given the chance. Personally, I wouldn’t miss this. Summer is fast approaching. Don’t miss this one!
$VIBI - Vilacto Bio Inc ?? Vilacto BioIP, LLC Holds 4 patents due to being in 4 different parts of the world.
Patent information:
Patented Technology ?? Vilacto Bio holds the worldwide patent for LACTOACTIVE iTHER®.
https://vilactobio.com/ip-patent-rights/
Nanoparticle Drug Delivery System (NDDS) patented technology:
https://www.globenewswire.com/news-release/2019/03/15/1755289/0/en/Vilacto-Bio-Canada-Patent-LACTOACTIVE-Granted.html
1. USA ???? - # 8,637,075
2. CANADA ???? - # 2,773,277
3. Europe ????/???? - # EP2341916
4. Hong Kong ???? - # HK1159997
SEC doc listing all the patents:
https://www.otcmarkets.com/filing/html?id=13603311&guid=-5jeUH--xIKxZth
“According to Patent No 8,637,075. a nanoparticle composition comprising colostrum Lactoactive® is formulated for treating diseases and/or conditions. Relieving the limited status due to the poor mechanical properties, rapid degradation, and in vivo clearance when bovine colostrum is used, our Lactoactive® is valuable to modify new bio/pharmaceutical industries.”
Video 1:
https://youtu.be/GZdfHqov6nE
Video 2:
https://youtu.be/LZVi8u0AVVk
______________________________________________
Bovine Colostrum & it’s importance to the human body:
- https://www.igbioscience.co.uk/_science/
“In May 2018, Vilacto Bio completed major upgrade to its Denmark production facility, which is owned by Pharma GP, can now accommodate the new compound formulations and smaller particle sizes that LACTOACTIVE iTHER® requires.”
Article:
https://vilactobio.com/lactoactive-ither/
Video:
https://youtu.be/_1TwKBun_pA
Message per company website:
“Invest in Viacto Bio and help improve emerging immunotherapies and antibody vaccines with antibody and antigen-rich colostrum in nanoparticle form.”
https://vilactobio.com/lactoactive-ither/
Sizes of their Nanoparticles (10nm - 300nm)
nm = nanometers
What Size of Particles are most effective?
https://www.engineering.com/story/the-future-of-medicine-is-at-the-nanoscale
- Turns out that the most effective measurement size for drugs is 1-100 nanometers. VIBI’s is 10-300nm, which falls well within those parameters.
- This size also allows them to cross the very crucial Blood-Brain Barrier (BBB), which more effectively allows patients with Parkinson’s, Alzheimer’s, & Type II Diabetes Mellitus (T2DM).
Blood-Brain Barrier (BBB):
https://www.michaeljfox.org/grant/dysfunction-blood-brain-barrier-cause-parkinsons-disease
______________________________________________
Strong evidence that points towards Vilacto Bio Inc. & Cantabio Pharmaceuticals forming a strategic partnership.
1. Pulse 2.0 published an article in December 2020 showing that on both company websites, the Investor Relation Contacts matched as the following:
- Toll-free IR Hotline: (844) 200-CTBO
- Email: ir@cantabio
Pulse 2.0 Article:
https://pulse2.com/vibi-stock-price-increases-vilacto-bio-160-why-it-happened/
2. Previously (in 2020) Cantabio’s website link on Twitter profile, when clicked on, went straight to Vilacto Bio Inc’s company web page. (This is also validated in the Pulse 2.0 Article).
3. Both Vilacto Bio & Cantabio Pharmaceuticals show the exact same wording on their websites which states the following:
“conducts in house R&D on critical elements of its drug discovery pipeline, while forming strategic alliances around novel technologies and outsourcing generic research activities to established contract research organizations.”
Sources to fact check:
- https://vilactobio.com/about-us/
- https://www.cantabio.com/about/overview.html
The 3rd piece of evidence, which is probably the most damning of all, shows that there is no doubt somehow a connection between these two companies.
______________________________________________
Now that we have established a direct connection between Vilacto Bio ($VIBI) & Cantabio Pharmaceuticals ($CTBO), we look at why they’d make a perfect fit for one another.
First let’s start with each company’s website:
Vilact has in fact 2 websites listed here ??
- https://vilactobio.com/bovine-colostrum/
- https://vilacto.com/
&
Cantabio Pharmaceuticals website:
- https://www.cantabio.com/about/overview.html
Information on both company’s websites:
??
Cantabio states the following:
How/Why Cantabio was formed ??
“The company was founded in Palo Alto, California in 2009 as Gardedam Therapeutics in order to pursue novel drug discovery research to develop pharmacological chaperones targeting a number of proteins linked to Alzheimer’s and Parkinson’s disease. The companies’ R&D was strengthened with an initial partnership with Dr. C. Rochet at Purdue University and Novalix and Gardedam was awarded two separate grants in collaboration with Dr. Rochet in 2010 and 2013 by the Michael J. Fox Foundation in support of its DJ-1 therapeutic project. Cantabio Pharmaceuticals, Inc. was established through the merger of Gardedam Therapeutics with Cantabio Pharmaceuticals in November of 2015.”
______________________________________________
Cantabio Pharmaceuticals receives major grant from Michael J. Fox Foundation to study Parkinson’s Disease, Alzheimer’s Disease, & Type II Diabetes Mellitus (T2DM):
Michael J. Fox Grant
September 16, 2020, Cantabio once again received a grant from the Michael J. Fox Foundation to study Parkinson’s Disease, Alzheimer’s Disease, & Type II Diabetes Mellitus (T2DM):
Cantabio Pharmaceuticals
https://www.biospace.com/article/releases/cantabio-pharmaceuticals-company-update/
Michael J. Fox Grant ?? DJ-1 Protein (unfolding)
“Grant enables the development of new detection technologies for DJ-1 in biofluids to create a new biomarker for the potential early diagnosis and tracking of the progression of Parkinson's disease.”
[The idea behind this is that the company would be able to hone in & identify where the disease starts by studying the DJ-1 protein and how it folds/unfolds.]
How do nanoparticles play a role in Parkinson’s?
- Nanoparticles Show Potential as Transport Agents for Parkinson’s Disease Treatments:
https://parkinsonsnewstoday.com/2020/11/13/nanoparticles-show-potential-transport-agents-parkinsons-treatments-to-brain-study/
Parkinson’s Disease & Blood-Brain Barrier (BBB):
https://www.michaeljfox.org/grant/dysfunction-blood-brain-barrier-cause-parkinsons-disease
______________________________________________
Connecting Vilacto Bio & Cantabio Pharmaceuticals through their technologies:
- Vilacto Bio first invented Lactoactive® for the treatment of anti-aging, psoriasis, rosacea, hives, and other serious skin diseases/disorders.
https://youtu.be/LZVi8u0AVVk
- Vilacto Bio then took it a step further & invented their patented Lactoactive iTHER which is “The most powerful grade of antibody-rich colostrum ever formulated.”
https://vilactobio.com/lactoactive-ither/
At Vilacto Bio, we have always known that LACTOACTIVE® – our pharma-grade colostrum compound, weaponized via nanotechnology – had a bright future in immunotherapy and vaccine development. Now, building on our success using LACTOACTIVE® to treat skin diseases, we are taking the next step with LACTOACTIVE iTHER®.
LACTOACTIVE iTHER® is a new LACTOACTIVE® variant built on our latest refinement techniques and even more precise and targeted fractionation. The compound will enable doctors to use injection, implantable and other delivery systems to send the richest form of colostrum available deeper into the body, where it is trained to penetrate cell walls and help the body fight diseases.
LACTOACTIVE iTHER® compound:
The LACTOACTIVE iTHER® compound will also enable the pharmaceutical companies we partner with to embed our potent compounds in their own immunotherapy and vaccine innovations. Emerging therapies for treating cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia and vitiligo all stand to benefit.
What is LACTOACTIVE iTHER®
BOVINE COLOSTRUM ??
https://vilactobio.com/bovine-colostrum/
LACTOACTIVE® – Grow, Repair and Protect
Colostrum is very rich in proteins, vitamin A, and sodium chloride, but contains lower amounts of carbohydrates, lipids, and potassium than mature milk. The most pertinent bioactive components in colostrum are growth factors and antimicrobial factors. The antibodies in colostrum provide passive immunity, while growth factors stimulate the development of the gut. They are passed to the neonate and provide the first protection against pathogens.
In human and animal cells, colostrum proteins have shown to interact with cell-surface receptors and influence processes such as morphogenesis, wound repair, and anti-inflammatory processes. But these factors can be limited due to the poor mechanical properties, rapid degradation and in-vivo clearance when bovine colostrum is used.
Bovine colostrum from pasture-fed cows contains immunoglobulins specific to many human pathogens, including Escherichia coli, Cryptosporidium parvum, Shigella Flexner, Salmonella species, Staphylococcus species, and rotavirus (which causes diarrhea in infants).
Look at this!!!?? ??
Immunoglobulin derived from Bovine Colostrum was used to develop first oral vaccine to treat & cure POLIO!!!
{“Before the development of antibiotics, colostrum was the main source of immunoglobulins used to fight infections. In fact, when Albert Sabin made his first oral vaccine against polio, the immunoglobulin he used came from bovine colostrum.”}
- Supplement the body’s antibodies with those contained in the compound
- Stimulate the body’s own ability to produce disease-fighting antibodies
Nanoparticle Drug Delivery System (NDDS):
“Thanks to this nanoparticle form, the compound also acts as an injectable nanoparticle drug delivery system (NDDS), able to penetrate affected cell walls and enter the cytoplasm to do its work.”
https://vilactobio.com/lactoactive-ither/
Great article from May 2018 about technology:
https://m.canadianinsider.com/vilacto-bio-inc-upgrades-denmark-plant-paves-way-for-new-lactoactive-ither-to-stimulate-local-antibody-production
??
Now let’s tie this NDDS to Cantabio Pharmaceuticals methods/techniques and what they are looking to achieve by utilizing the small molecule/nanoparticle drug delivery system (NDDS).
Cantabio Pharmaceuticals:
Company focuses on small molecule approach to research the DJ-1 Protein unfolding/folding in order to locate target site for the origination of Parkinson’s Disease, Alzheimer’s, Type II Diabetes Mellitus (T2DM).
Company has 4 drugs it is working on currently:
CB101 - PARKINSON'S DISEASE
DJ-1 targeting small molecule pharmacological chaperone
CB201 - DIABETES Cell penetrant DJ-1 protein
CB301 - ALZHEIMER'S DISEASE
Tau targeting small molecule pharmacological chaperone
Licensed from University of Cambridge - cellular and in vivo data, ongoing in vivo studies
CB401 - PARKINSON'S DISEASE
DJ-1 biomarker for Parkinson’s diagnosis
- Currently in proof of concept studies
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087133&_ga=2.268988657.1815687588.1620093771-1520470649.1619903608
Here’s the connection:
Cantabio Pharmaceuticals & Vilacto Bio focus on small molecule/nanoparticle drug delivery systems (NDDS) in order to locate target sites ?? Cantabio can utilize that technology to target DJ-1 protein ?? a-synuclein ?? hone in on origin of Parkinson’s Disease (possibility) ?? possible vaccine/immunotherapy treatment(s) for Parkinson’s, Alzheimer’s, & Type II Diabetes Mellitus (T2DM)
??
***That’s why there could be a huge merger/acquisition here!!!***
Biochemistry of Parkinson’s Disease:
https://scholar.google.com/scholar?q=New+%CE%B1-and+%CE%B3-synuclein+and+DJ-1+protein&hl=en&as_sdt=0&as_vis=1&oi=scholart#d=gs_qabs&u=%23p%3D-xqjjTGqx5kJ
______________________________________________
This is what makes the strategic partnership between Vilacto Bio & Cantabio Pharmaceuticals so obvious & absolutely necessary. Both companies working together to formulate groundbreaking technologies in order to locate where Parkinson’s, Alzheimer’s, & T2DM originates on a micro-cellular level, so they can create a vaccine or immunotherapy treatment(s).
Vilacto Bio & Cantabio ?? nanoparticle drug administered through Nanoparticle Drug Delivery Systems (NDDS) ?? to treat/cure Parkinson’s Disease, Alzheimer’s, Type II Diabetes Mellitus, & possibly cancers (listed on both company’s websites)
$VIBI - I hope you are all ready for a monster move coming from this stock. It is being accumulated and building up momentum. Don’t let the low volume & price dip fool you. That’s what happens when the deep pockets buy up millions of shares. A big push is coming. Some rumors are flying around about a deal with Cantabio Pharmaceuticals who has the Michael J Fox grant. Which I’ve stated here before. Rumors have been swirling since December 2020 & may be finally coming to light. “Buy the rumor, sell the news.” VIBI’s low O/S is a penny stock traders wet dream. It’s going to explode upwards. Be ready. Could come tomorrow, could come in a week or two. My recommendation is get a low position now before it moves up any further. Catch the buys on the dips. Dip & Rip is in session. I told you all to watch the volume the other day. MM’s holding it down. Fake orders are in making sure to hold it under $.0018 so they can accumulate. It’s about to go. Could be tomorrow could be in a week. You do not want to miss this move. No pump, just a friend coming here to strongly suggest you take a look at VIBI & what is going on. Big move is coming.
$VIBI - Vilacto Bio ?? Cantabio Pharmaceuticals
- Both companies share the same Investment Relations contact information. There is no disputing this. Shows it on both of their websites.
Contact info for both us:
ir@cantabio.com
(844) 200-CTBO
IT’S UNDENIABLE!!!
Here’s Pulse 2.0 reporting about the IR info connection between Vilacto Bio & Cantabio Pharmaceuticals.
https://pulse2.com/vibi-stock-price-increases-vilacto-bio-160-why-it-happened/
This was not too far back: article written in December 2020 and no one fact checked it so I did. It’s legit AF. I even called the investment relations phone numbers for both companies and asked for Investment Relations contact info and they gave me the same info without me mentioning the connection at all. It’s LEGIT!!!
$VIBI - Vilacto Bio ?? Cantabio Pharmaceuticals
?Type II Diabetes Mellitus
?Both work on immunotherapies
?VIBI has never done a Reverse Split (no R/S)
?Michael J Fox Foundation = grant ?? to Cantabio for Parkinson’s, Alzheimer’s, & Type II Diabetes
VIBI working on Type II Diabetes Mellitus (T2DM)
https://vilactobio.com/vilacto-bio-offering-natural-alternatives-to-strong-drugs-in-the-psoriasis-and-diabetics-market/
Cantabio Pharmaceuticals receives grant from Michael J Fox Foundation to work on Parkinson’s Disease, Alzheimer’s Disease, & Type II Diabetes Mellitus (T2DM)
DD Part 1
https://twitter.com/homelssmillionr/status/1385248045361631235?s=21
DD Part 2
https://twitter.com/homelssmillionr/status/1385248055440527361?s=21
Additional information for VIBI & Cantabio:
All I can say is I am and have been buying this on all the dips. VIBI’s last max peak hit $.69
Prior to that it hit peaks of $.50, $.80, $1.37 & the low points between the peaks were hitting $.26, $.21, $.25, & $.45 (starting with most recent and going backwards).
You’ve all seen these biology related stocks soar: CELZ, BRTX, RMSL, INND, RGBP...etc. Are you really not going to take a chance on this stock that has a small O/S of 3.30 Billion, compared to other bloated stocks out there? Plus their financials are listed as “Audited” on OTC markets websites which is not usual. Plus we have a bunch of people backing this stock with legit info? If you cannot see where this is going you don’t deserve to hold the stock. It’s a risk I firmly believe is worth taking at the price it is now. It’s going to go crazy IMO.
https://twitter.com/homelssmillionr/status/1385248895274467328?s=21
VIBI is a sure fire win in my book!
Does everyone here see where this is pointing? The subsidiary $COHO/Rechtman is talking about in documents, and the company TKIU is going to Reverse Merge into is $PDGO - Paradigm Oil & Gas, Inc. If I were you all I’d be loading up $PDGO today and loading it like crazy. This is a monster in the making!!! Easy multi-penny stock with its SS/Float.
Shows TKIU taking control of PDGO from previous controlling shareholder (NIRA Petroleum Corporation) through a Stock Purchase Agreement (SPA).
https://www.sec.gov/Archives/edgar/data/1191354/000149315220014836/form8-k.htm
Give credit to this individual - Stock_Goodies on iHUB. I found the posting doing a Google search/iHUB and Stock_Goodies helped lead me to the companies, then I made the final connection. COHO has control of TKIU and TKIU has control of PDGO. Which means COHO has control of both of them. Connect the dots. Huge deal. Now watch PDGO’s stock price soar over a penny. Investors love a good puzzle to solve and it makes the DD all that much sweeter. When people find this they’re going to be all over $PDGO!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156845249
https://www.globenewswire.com/news-release/2020/09/08/2090250/0/en/Crednology-Holding-Corp-Issues-Statement.html
Stock_Goodies - Post on iHUB:
Stock_Goodies Saturday, 07/11/20 10:20:10 PM
Re: getmoreshares post# 113068 0
Post # of 114056
Top Knot Inc, USA lists it's directors/officers as "Corporation Service Company"
https://opencorporates.com/companies/us_ny/5569807
Top Knot Inc and CSC also share the same address https://80state.com/tenants/
Corporation Service company: www.cscglobal.com
"Trusted Service Provider To The World's Most Recognized Brands And Law Firms. Trusted Since 1899"
"CSC® has helped corporations meet their legal, compliance, tax, and online brand challenges for more than a century. We are the unwavering partner for hundreds of thousands of business customers, providing services for every phase of the business lifecycle in all 50 states, as well as globally."
"We are the unwavering partner for 90% of the Fortune 500®, more than 65% of the Best Global Brands (Interbrand®), nearly 10,000 law firms, and more than 3,000 financial organizations. Headquartered in Wilmington, Delaware, USA, since 1899, we have offices throughout the United States, Canada, Europe, and the Asia-Pacific region. We are a global company capable of doing business wherever our clients are and we accomplish that by employing experts in every business we serve."
Looks like Top Knot was just the middle man between Crednology and Stonecrest for the transfer of the company...and a super legit middle man at that!!!
Email Response received from individual/employee connected to Arista Financial Corp (ARST). I reached out to the working/valid email in my previous post. I received a response from the individual, Tony, who stated he is a former employee of the company. So don’t email Tony any longer. Company currently does not have a valid email address or phone number. If someone locates one that works please post it to the forum. Thank you
Please do not use this email: tony@investorawareness.com for ARST
Here is the email exchange between myself and Tony.
On Sat, Feb 13, 2021 at 5:48 PM <ME> wrote:
Hello,
I am an investor inquiring about Arista Financial Corp (ARST) and Arista Mobile Group Ltd (AMG). Could you provide me with any recent news/activity pertaining to the company? Also, is the company planning on completing a Reverse Split? Thank you so much for your time. Have a wonderful day.
Sincerely,
ME
——————————————————————————————————————————————————
On Sat, Feb 13, 2021 at 7:01 PM Tony Schor <tony@investorawareness.com> wrote:
I have not worked with the company for almost a year. My suggestion is to reach out to them directly. All the best, Tony
——————————————————————————————————————————————————
On Sat, Feb 13, 2021 at 8:02 PM <ME> wrote:
My apologies Tony. Thank you for the fast response. I did reach out to them but their email and phone number are not working. They may not have the current one posted online. Thank you for your time.
Arista Financial Corp (ARST) & Arista Mobility Group Ltd (AMG): DD
https://www.aristafinancial.com/
CEO - William J Caragol (Bill Caragol) resigned on May 5, 2020.
https://investorshub.advfn.com/Arista-Financial-Corp-ARST-31765/
Resigned: Chief Financial Officer (CFO) - William J. Caragol (Bill Caragol)
On May 5, 2020, William J. Caragol resigned from his position as the Chief Financial Officer of the Company effective immediately. The Company expects that Mr. Caragol will remain available to provide certain consulting services to the Company as needed. Mr. Patrizio, the Company’s Chief Executive Officer will assume the role of interim Chief Financial Officer until such time as a replacement can be appointed.
On May 5, 2020, Kenneth Mathews resigned from his positions as Director, Secretary and Treasurer of the Company effective immediately. On May 5, 2020, R. Scott Williams resigned from his position as Director of the Company effective immediately. As a result of these resignations, Mr. Patrizio is the sole director of the Company.
“Short Hills, New Jersey, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Arista Financial Corp., a financial service holding company (the “Company”) (ARST), announced today that it has appointed William J. Caragol as its new Chief Financial Officer. Mr. Caragol has extensive experience with growth stage microcap companies in finance, mergers and acquisitions, business development and accounting.”
https://www.aristafinancial.com/team.html (should be updated before too much longer)
Arista Mobility Group Ltd. (“AMG”): Currently listed as expired.
https://www.sec.gov/Archives/edgar/data/1498122/000121390020001754/f8k012220ex99-2_aristafin.htm
Company subsidiary (AMG) listed as expired currently: ??
https://nevada-biz.com/co/arista-mobility-group-ltd
Arista’s Mobility Subsidiary to Target Carsharing Market, Estimated at $12 Billion by 2024
News Update:
https://finance.yahoo.com/news/arista-financial-corp-announces-2020-142129276.html
https://sec.report/Document/0001213900-19-019489/
I’ve called the company phone number and sent emails but the phone number doesn’t work and the email addresses that I have do not work. I did find a 2nd email for investor relations. It’s the top 1 below:
tony@investorawareness.com (works)
info@aristafinancial.com (doesn’t work) - I sent a message to this email
Phone: (973) 218-2428 (doesn’t work)
Link to company contact form: https://www.aristafinancial.com/contact-us.html (seems to work)
I’ve sent in a contact form requesting information pertaining to any recent company activity and asking if they plan on doing a Reverse Split anytime in the near future to help protect us all and keep us all informed.
Pink No Information: Currently Stop Sign due to
? Delinquent SEC Reporting (not good but share price will skyrocket if they bring to current status)
?Verified Profile 11/2020 (this is good)
? Transfer Agent Verified (this is good)
Source: www.otcmarkets.com
ARST SECURITY DETAILS - Stop Sign ??
Share Structure:
Market Cap Market Cap: $3,112,882 @ $.0037 pps - 02/12/2021
Authorized Shares: 1,980,000,000 - 02/02/2021
Outstanding Shares: 841,319,477 (this is low enough no R/S is actually needed). 02/02/2021
Restricted: 3,121,952 - 02/02/2021
Unrestricted: 838,197,525 - 02/02/2021
Held at DTC: 837,722,229 - 02/02/2021
Float: Not Available
Source: E*TRADE & TD AMERITRADE chart history
NOTE: Chart history shows the following
06/15/2019 - peak pps (price per share) hit $.55 - keep in mind the company completed a Reverse Split on
10/13/2017; 1:13.2 R/S - if we were to use this to calculate previous True Peak Value Max (TPVM) it would mean their last peak potential was actually $.0416 (we reverse the Reverse Split to calculate this) and if we go back to the previous peak before that (true peak), it gives us a future pps peak of max $.1121 (30x multiplier from where it is right now - $.0037).
Here’s how to calculate this:
Max peak share price hit $1.48; we divide this number by 13.2 (Reverse Split in Reverse).
$1.48/13.2 = $.1121 new estimated True Peak Value Max (TPVM).
$.55/13.2 = $.0416
Estimated TPVM range = $.0416 - $.1121 (11-30x multiplier potential)
Possible Future Catalysts:
- Announcement of new CEO/CFO & Board members
- Company producing new positive filings/becoming current in filings to upgrade from Stop Sign tier to Pink Current
- PPS hits new level (if it clears a penny, it will gain attention of new investors). Think, each investor has a “Purchase/Trade Zone” that they prefer to trade in. Some investors trade in multiple zones. Some investors trade in specific zones such as: trips, some in doubles, some when it hits a penny, and so on. A stock price reaching a new “Purchase/Trade Zone” is a catalyst in and of itself. This drives the share price further upwards into a new trading level/tier.
I’m using all available predictions based off the fact this runs, like other stocks have, prior to any Reverse Split taking place. Please be advised these are ONLY MY OPINIONS. Make sure you conduct your own solid DD.
Check out this DD!! - This can definitely run to copper land. Big pennies possibly. Dude is dropping ridiculous info. How come no one else here is posting this stuff? We need to work together and grab more DD. I’ve got 13+ million shares. Let’s make this move!!!!!!
https://twitter.com/homelssmillionr/status/1352567057548595203?s=21
https://twitter.com/homelssmillionr/status/1352571190200606720?s=21
https://twitter.com/homelssmillionr/status/1352567742482669568?s=21
$GTLL - expect this stock to run like $PLYZ did recently. Very similar Share Structure (SS). This can run high 20’s, maybe even more if the company drops news. PLYZ ran almost to $.0030 with a shit SS and no news other than it might become current in January 2021. GTLL will be Pink current again soon and has recent news. More news could drop any day now too. There is enough factual evidence mounting that leads me to believe that GTLL will be completing a Reverse Merger with MOM so that it then belongs 100% to BBIG. It’s either that or BBIG is going to announce it is acquiring GTLL. One of those possibilities is extremely likely to happen and happen soon based off of evidence where BBIG states that Markets on Main is its platform. GTLL has stated on 09/23/2020 that it owns Markets On Main (MOM). Something big is going down.
$OPTI ?? Markets On Main (MOM) ?? $GTLL ?? Vinco Ventures ($BBIG)
Big connection here and GTLL has been working since 2/27/2020 to retire nearly 4 Billion shares.
https://twitter.com/globaltechgtll/status/1233024654899654656?s=21
InvestorsHub
Date: December 17, 2020
OPTEC International, Inc. (OPTI) to Hold Annual Shareholder Call via Zoom
Symbol: OPTI
OPTEC International, Inc. (OPTI) to Hold Annual Shareholder Call via Zoom
CARLSBAD, CA -- December 17, 2020 -- InvestorsHub NewsWire -- OPTEC International, Inc (OTC Pink: OPTI), A developer of UV and UV-C safety products and related advanced technologies specific to Personal Protection Equipment (PPE), today announced that it will be holding the annual shareholder call via Zoom on December 29, 2020.
CEO, Roger Pawson, stated "We have decided to schedule the annual shareholder call at the end of this month to review the company's 2020 overall status.
Please email your questions to: Investor@optecuvc.com and we will address as many of the questions as we can during the call".
The purpose of the call is to provide a year-end update of the company's progress and growth and answer pending questions to provide clarity and future expectations to our shareholders. The Company will post the call-in details via press release and on the website prior to the call. Furthermore, an audio copy of the shareholder call will be published on www.Optecintl.com for the benefit of shareholders who cannot attend on December 29, 2020 will still be able to hear all that will be discussed.
About OPTEC International, Inc.
With Locations in Carlsbad and Vista, California, OPTEC International is a developer and manufacturer of electronic LED, Ultraviolet (UV) & UV-C safety products and related advanced technologies and PPE (Personal Protection Equipment) products. The company's Safe-Scan product line is being launched at a time when HR directors and facilities managers are experiencing extreme concern with respect to keeping environments safe during the global pandemic crisis and the safe reopening of the U.S. economy. For more information visit: www.optecuvc.com
Safe Harbor Statement: Safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as Opti, OPTEC or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. OPTEC International Inc.
OPTEC International, Inc.
Investor Relations Contact:
Andrew Barwicki
516-662-9461 / Andrew@barwicki.com
Source: OPTEC International, Inc.
View source version on Investorshub.com: https://ih.advfn.com/p.php?pid=nmona&article=83931353
——————————————————————————
InvestorsHub
Date: December 9, 2020
OPTEC International, Inc. (OPTI) Shareholder Update Letter December 2020
Symbol: OPTI
CARLSBAD, CA -- December 9, 2020 -- InvestorsHub NewsWire -- OPTEC International, Inc (OTC Pink: OPTI), a developer of UV and UV-C safety products and related advanced technologies specific to Personal Protection Equipment (PPE), today released a shareholder update letter.
To our Shareholders,
I would like to start by thanking each and every one of our shareholders for their continued support of Optec International, Inc. I am pleased to report to you on our 2020 year to date progress and share our outlook for the balance of the year. The Company has grown tremendously over the year as evidenced by the increase in revenues, and we believe we are well positioned to continue to deliver value for our shareholders. Some of the developments we would like to highlight and update the shareholders on include:
We closed a $5,000,000 funding deal with RB Capital Partners, Inc., creating a solid financial foundation for growth in the coming year. As of today, RB Capital has funded $4,600,000 of the $5,000,000 deal with Optec. The primary use of funds has been for the iWandä production and distribution in addition to financing the PPE deal. The funding partnership not only signifies the support of a long-term financial partner, but also indicates that we have paid off all other harmful debt. The investment money provided by RB Capital is completely non-toxic, non-dilutive and is in the best interest of the Company and the shareholders as the it has a fixed conversion price of $0.70 per share.
The company is finalizing the logistics portion of the recent $2B PPE purchase order and is anticipating completion by the end of the month. It is expected that the revenue portion of this transaction will be reported on the December 31, 2020 quarterly report.
We surpassed our previous quarter’s income and revenue by over 600% for the period ending September 30, 2020. The Company surpassed its $4,000,000 projection for the quarter ending September 30th and, in fact, showed revenue and income totaling $6,284,609 and a net income of $3,381,730. In addition, the Company has paid in full all previous convertible institutional notes and the interest and liabilities associated with those notes. We project an increase in revenue over last quarter for Q4.
We signed an exclusive distribution deal with the country of Greece for the Optec UV, UV-C, and other North American Distributors for the company’s PPE product lines. We continue to provide and ship our products to distributors on a regular basis.
We signed contracts with several large retail outlets for the sale of our UV-C product line. We understand that the public is eager to know the specific names of these retails, but at this time we are contractually bound from releasing those names. We will soon be able to release this information to the public and look forward to doing so.
Optec International, Inc.’s Fuel Maximizer Product Line. The company continues to manufacture, promote, and sell the fuel maximizer product line nation-wide.
Optec appoints Dr. Drew Pinsky, nationally known television, radio, and podcasting host and New York Times bestselling author as Brand Ambassador. Dr. Drew will help to open up increased distribution opportunities. We announced a new agreement with Vinco Ventures, Inc. (NASDAQ:BBIG)
On December 3, 2020 for the distribution of our iWandä and the Hydroxyl Portable Air Sterilizer.
We have successfully launched our Touchless Safe- Scanners and Rovers within several different school districts. To date, we have implemented our Touchless Safe-Scanners and Rovers to both local and nationwide school districts. It remains to be seen when all schools will be given the green light to fully re-open, but we have strong relationships with several school districts around the country to be able to ship more product and enable a safe re-open when allowed.
The Harrington Group is launching a nation-wide Campaign for the iWandä. Kevin Harrington and his group will be launching their own social media campaign marketing the iWandä to their network and beyond. This campaign coupled with the promotional billboards around Los Angeles will continue to increase market awareness for this product.
Forecast and Outlook for 2021. We plan on uplisting to the QB in the beginning of Q1 and have already started the process. We also plan on applying for Penny Stock Exempt status as we will soon meet the criteria. Based on our current growth, we anticipate the Company will be preparing for an uplist to the Nasdaq at some point in the later part of 2021 or early 2022 as we currently meet many of the requirements for that exchange. Optec also expects that revenues will continue to exceed all expectations as several other large PPE deal are going to be completed in 2021.
About OPTEC International, Inc.
With Locations in Carlsbad and Vista, California, OPTEC International is a developer and manufacturer of electronic LED, Ultraviolet (UV) & UV-C safety products and related advanced technologies and PPE (Personal Protection Equipment) products. The company's Safe-Scan product line is being launched at a time when HR directors and facilities managers are experiencing extreme concern with respect to keeping environments safe during the global pandemic crisis and the safe reopening of the U.S. economy. For more information visit: www.optecuvc.com
Safe Harbor Statement: Safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as Opti, OPTEC or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. OPTEC International Inc.
OPTEC International, Inc.
Investor Relations Contact:
Andrew Barwicki
516-662-9461 / Andrew@barwicki.com
$OPMZ - 1pm Industries
Has a good Share Structure(SS):
O/S: 4,262,786,083
Market Cap: $852,557 @ $.0002
Von Baron Farms
https://www.instagram.com/vonbaronfarms/?hl=en
https://www.newcannabisventures.com/tag/von-baron-farms/
https://www.sec.gov/Archives/edgar/data/859747/000156761920001248/doc1.htm
OPMZ
Earlier today I posted incorrectly about the CEO. I identified the wrong person as the CEO. I said the CEO was John M. Fife. John M. Fife is not the CEO, he is a toxic lender who has a horrible track record and takes advantage of companies who aren’t doing well. The CEO of OPMZ is Joseph Wade. Joseph Wade has been with the company since 2015. Please disregard what I said earlier in reference to dumping your shares. I’ll have to buy mine back if I want any. I’m going to do better DD for this company and for the investors here. My apologies for providing bad DD and I take full responsibility for it. I will correct it. Hold tight and I’ll come back with very solid DD.
$OPMZ
INVESTORS BEWARE:
https://twitter.com/homelssmillionr/status/1340274622395125760?s=21
https://www.securitieslawyer101.com/2020/sec-says-toxic-funder-john-m-fife-is-an-unregistered-dealer/
Fife has operated as what’s called a “toxic lender” for many years. Microcap companies trading on the over-the-counter market typically have limited access to traditional financing. Desperate for cash, they sign on with financiers like Fife who purchase securities—usually convertible promissory notes or convertible debentures—from them. The financiers charge extremely high interest, but that’s the least of their clients’ problems. Upon conversion, the lenders enjoy a discount to market price that may be as high as 60 percent, and higher in the event of default by the issuer. As he converts portions of his note and sells the resulting stock into the market in a series of tranches, the stock’s price plummets. That is why these kinds of instruments are called “death spiral convertibles.” Eventually, the dilution caused by the conversions may force the issuer to reverse split the company’s stock. Sometimes it drives the company into bankruptcy.
Notice the terminology “death spiral convertibles”
I dumped my shares. Had 10 million until I found this article.
Marijuana stock or not, this is garbage. SS doesn’t matter when the CEO is crooked and a horrible businessman.
My strong recommendation, dump your shares and find another stock that is solid to invest in.
Get out and don’t look back on this one.
Have a good day.
This is no P&D I can assure you of that. When the price drops super low and everyone starts talking negatively and dumping their shares because they’ve given up hope, news will drop and this will rise from the ashes. It will leave the non-believers in the dust, and the true believers will reap the reward of holding. Just wait you’ll see. News is coming.
Get ready for this to go as early as tomorrow. It goes over the next few days for sure. Watch the volume tomorrow morning. Get those orders in.
Stock pick of the week: $HPIL
HPIL Holding is a development stage company, which engages on investing in companies, whether public or private enterprises. It also focuses on acquisition of intellectual properties and technologies, with interest in the healthcare and environmental quality sectors.
Great SS - yes they need to file to bring it current, but as is this ticker looks amazing and can run up easily like $AFOM with enough volume. It can rocket up quickly.
No Reverse Splits EVER!!!!!!!
https://www.otcmarkets.com/stock/HPIL/security
Nitin M. Amersey
Chairman, President, CEO & Secretary
Ray Wong
Chief Operating Officer
David C. Langle
Chief Financial Officer
John B. Mitchell
Independent Director
$HPIL acquired: Rudy Enterprise Inc, a building/construction company.
Rudy Enterprise Inc - So far has $430,682 revenue for 2020.
https://www.dnb.com/business-directory/company-profiles.rudy_enterprise_inc_7_99.55417ce0047be71d300a570e33761fb1.html
https://www.sec.gov/Archives/edgar/data/1286345/000121390019006556/f8k041719ex99-1_hpilholding.htm
https://cofs.lara.state.mi.us/CorpWeb/CorpSearch/CorpSearchViewPDF.aspx
https://michigan-company.com/co/rudy-enterprise-inc
https://local.yahoo.com/info-30523293-Michael-J-Rudy-Builder-%26-Project-Center;_ylt=Awr9ImvNU81fISoAVz5wVdx_;_ylu=Y29sbwNncTEEcG9zAzEEdnRpZAMEc2VjA3Nj?p=Michael+J+Rudy+Builder+%26+Project+Center&ei=UTF-8&selectedId=30523293
https://start.cortera.com/company/research/k6s4ssq3p/rudy-enterprise-inc-7-99/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158771100
Hi. I heard awhile back they said something about completing a Reverse Split sometime soon in their 8-k or 10-Q. Did anyone else see that and has anyone heard any recent news about whether or not they’re doing it? I ask because WDLF did the same thing then supposedly revoked the RS and then the stock took off. I don’t want to miss this. If they don’t complete one, then we should be loading this. It’ll payout millions!!! This goes minimum $.04. Look at all the Pink stocks starting to take off, especially ones with good SS’s. ABCE & IRNC have fantastic SS’s. These can hit pennies no problem and in a hurry.
Rumor has it some big investors are loading up on this stock plus a Twitter user by the name of Homeless Millionaire who uses a group to load up shares and move legitimate tickers. Not sure when this might happen. Looks to be soon though. The SS isn’t that great honestly but it has been over a penny before. Maybe this could hit around $.013 if we’re lucky. Stock’s stats:
https://www.otcmarkets.com/stock/UBQU/security
This company has a decent SS. Market Cap is pretty good considering. Volume has been gradually increasing. This could eventually run within the next 30-45 days. Will be fun to see if it goes. I only have a couple million of this @ $.0001. Let’s see what happens in the upcoming weeks.
Bam did I call it or what?! Chalked up another early call. The SS is going to let this run way up and fast. Do not, and I repeat do not sell this anytime soon. Even without news from CEO the share structure and float are going to allow this to go sky high. We might see $.05+ by end of December. Hold this. All the trip stocks are being pushed and the legit ones, like AFOM, are going to soar. Keep in mind the company is in contract to complete 20 movies over the next 5 years with producer, director, writer - Jeff Deverett. Deverett has already had 3 movies on Netflix that are contracted to run for 3 years. He’s done 7 feature films. Tell all your investor friends and get them in early. This runs hardcore. Stock was hurt by pandemic but they still file, just a little behind. Get this loaded now before people find out about it. It has major attention due to major volume. Don’t get caught hesitating, LOAD, LOAD, LOAD. Looking for $.10
https://www.prnewswire.com/news-releases/all-for-one-media-enters-into-agreement-to-produce-20-movies-300880543.html
https://www.prnewswire.com/news-releases/all-for-one-media-afom--otcqb-announces-production-of-perfect-10--full-out-2-to-commence-on-august-8th-under-previously-announced-production-and-netflix-licensing-deal-300892114.html
Rumor has it big things are in the works. Only time will tell. There may be something brewing behind the scenes. Next week I’m excited to see if anything materializes from this volume. I’ve been holding long 20 million shares. Hopefully this goes somewhere. Keep a close watch come Monday everyone. Fingers crossed we actually make some good money from this. Come on give us a runner...
This is rolling. Trying to get to 80 million. We could see this run. It just needs to hit 250 million trade volume and it’ll start getting crazy attention. If it moves to $.0003 it’s over, at that point it will run within a week or two. Still over an hour 15 minutes before the market closes. Get everyone you know in on this because it won’t be @ $.0001 for much longer. Once 1’s go, 2’s will start to fall quickly!!! Semi-Low O/S which will allow this to run up quickly. Get your shares now @ $.0001 while you can!!!
This stock is starting to get some attention. I now have 4 million now. Thank you for whoever offloaded. I’ve been watching this stock for a couple of months now and it can go big in a hurry. The market is picking up steam now, perfect time for this one to gain some traction. I hope you all use Twitter, there are some good charts and analysis on there. Check Stock Jocks group on Facebook. They’re talking about it there. This morning it was getting attention. Look for this to run by Jan 1st. This stock is going to climb quickly. It just needs to get noticed.
It’s runs to $.0050-$.01 bases on chart analysis and past history. This stock is going to run get out if you want to but I’m telling you, this is going to go. There’s no REVERSE SPLIT coming so the only way is legitimately up at some point, and soon.
If there isn’t any mention of a Reverse Split, this runs north between $.0050-$.01
Get out of this stock while you can before you lose your asses. Big Reverse Split coming by January. Price could run up a little but don’t chance it. Just dump your shares and find something better to invest in like $NWBO & $GAXY. This stock is done.
QuadraMune ™? in Phase II trials to test for possible Covid-19 treatment and to treat Type II Diabetes. Previously $TSOI researchers came up with the idea to test QuadraMune ™? with the world’s #1 diabetes drug, Metformin. Results found from that study prompted it to be tested in this study on humans. If this nutraceutical, QuadraMune ™? shows great improvement in cardiovascular health dealing with Covid-19 symptoms and also enhances the positive effects of the Metformin for diabetics this would be huge. IBRC & TSOI stocks would soar. Even if only one of these shows statistically significant positive results it could drive the share prices up. Here is a long analytical write-up that includes previous studies associated with QuadraMune. Keep in mind, $TSOI is the scientific company that created and is testing the drug, while IBRC is more the marketing and distributing company for the drug. Who knows which company’s share price will increase the most, better grab shares of both to make sure.
$IBRC - iBrands Corp
$TSOI - Therapeutic Solutions Intl
Current prices:
$IBRC - $.0001 (52-Wk High: $.0003 on 6/29/20)
$TSOI - $.0066 (52-Wk High: $.023 on 6/15/20)
$TSOI - scientists have a nutraceutical called QuadraMune.
$IBRC - helps market and sell the product for $39.99 on the website @ www.youcanordernow.com
https://www.youcanordernow.com/QuadraMune%E2%84%A2-60-Capsules_p_34.html
QuadraMune™ 60 Capsules
QUADRAMUNE™ 60 CAPSULES
Your Price:$68.00
Retail Price:$89.00
Part Number:QuadraMune™ 60 Capsules
Description
QuadraMune™ - A synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. For more information visit https://areyoucovidmune.com/covidmune/
———————————————————————
CURRENT CLINICAL STUDY:
Major clinical trial involving QuadraMune and its effects on Covid-19 and also its effects on Type II Diabetes when paired with world renowned diabetes drug, Metformin (first & #1 prescribed drug in the world for Type II diabetes).
QuadraMune(TM) for Prevention of COVID-19
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04421391
Recruitment Status : Recruiting
First Posted : June 9, 2020
Last Update Posted : June 9, 2020
See Contacts and Locations
Sponsor:
Therapeutic Solutions International
Information provided by (Responsible Party):
Therapeutic Solutions International
Study Details Tabular ViewNo Results PostedDisclaimerHow to Read a Study Record
Study Description
Go to sections
Brief Summary:
QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies. The current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune(TM) in reducing infection in individuals at high risk of COVID-19.
Condition or disease Intervention/treatment
Phase
Covid19
Coronavirus
SARS-CoV 2
Dietary Supplement: QuadraMune(TM)
Detailed Description:
QuadraMune(TM) is composed of 4 natural ingredients.
Pterostilbene is an analogue of resveratrol, and has been shown to possess antiinflammatory activity. Additionally, this compound suppresses macrophage activation while enhancing NK activity.
Epigallocatechin gallate (EGCG) is one of the active ingredients in green tea and has been shown to act as an activator of T cells, and a suppressor of neutrophil mediated inflammation.
Sulforaphane is derived from broccoli and studies have shown that it protects lungs from inflammatory pathology.
Thymoquinone, which is chemically related to hydroxychloroquine, possessing antiviral effects and increases NK activity.
QuadraMune is a combination of these ingredients and is believed to possess superior in vitro and in vivo therapeutic properties as compared to when the ingredients are administered individually.
The study aims to assess preventative effects of QuadraMune(TM) administration for 12 weeks.
Study Design
Go to sections
Study Type :
Interventional (Clinical Trial)
Estimated Enrollment :
500 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase II Study of QuadraMune(TM) for Prevention of COVID-19 in High Risk Populations
Estimated Study Start Date :
June 8, 2020
Estimated Primary Completion Date :
November 1, 2020
Estimated Study Completion Date :
November 8, 2020
Resource links provided by the National Library of Medicine
Genetic and Rare Diseases Information Center resources: Severe Acute Respiratory Syndrome
U.S. FDA Resources
Arms and Interventions
Go to sections
Arm Intervention/treatment
Experimental: Treatment Arm
Patients will receive 2 pills of QuadraMune(TM) daily for 12 weeks
Dietary Supplement: QuadraMune(TM)
QuadraMune(TM) is a commercially available nutritional supplement
Outcome Measures
Go to sections
Primary Outcome Measures :
Prevention of COVID-19 [ Time Frame: 12 Weeks ]
Prevention of COVID-19 symptoms as recorded in a daily diary
Secondary Outcome Measures :
Safety as determined by presence or absence of Adverse Events and Serious Adverse Events [ Time Frame: 12 Weeks ]
Assessment of adverse events and serious adverse events will be performed.
Eligibility Criteria
Go to sections
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 120 Years (Adult, Older Adult)
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Criteria
Inclusion Criteria:
Informed consent, provided electronically via the EDC, demonstrating the subject understands the procedures required for the study and the purpose of the study Male or female patients 18 years of age or older that are considered to be high-risk individuals.
High-risk individuals are defined as all health care workers in hospitals, clinics, and emergency rooms, and medical facilities.
Subjects must agree to practice at least two highly effective methods of birth control for the duration of the study This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. At least one of these must be a barrier method. Subjects not of reproductive potential will be exempt (e.g. post-menopausal, surgically sterilized).
Exclusion Criteria:
Refusal to provide informed consent Any previous positive test for COVID-19 by RT-PCR Symptomatic for COVID-19 Diarrhea prior to the start of treatment Type I or II diabetes Atherosclerotic Coronary Artery Disease
Any contraindication for treatment with hydroxychloroquine including:
Hypoglycemia G6PD deficiency Porphyria Anemia Neutropenia Alcoholism Myasthenia Gravis Skeletal muscle disorder Maculopathy Changes in the visual field Liver disease, with ALT/AST > 2.5 upper limit normal and total bilirubin >2.5 upper limit normal Psoriasis Any comorbidities which, in the opinion of the investigator, constitute health risk for the subject.
Contacts and Locations
Go to sections
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04421391
Contacts
Contact: Thomas E Ichim, Ph.D 18583534303 thomas.ichim@gmail.com
Locations:
United States, California
Therapeutic Solutions International Recruiting
Oceanside, California, United States, 92056
Contact: Thomas E Ichim 858-353-4303 thomas.ichim@gmail.com
Sponsors and Collaborators
Therapeutic Solutions International
Investigators
Principal Investigator: James Veltmeyer, MD Therapeutic Solutions International
More Information
Go to sections
Responsible Party:
Therapeutic Solutions International
ClinicalTrials.gov Identifier:
NCT04421391 History of Changes
Other Study ID Numbers:
QuadraMune002
First Posted:
June 9, 2020 Key Record Dates
Last Update Posted:
June 9, 2020
Last Verified:
June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Therapeutic Solutions International:
Immunology
Innate Immune System
Additional relevant MeSH terms:
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Major Clinical study set to conclude between 11/01/20-11/07/20
- 3rd party has to validate research results which should take 2-4 weeks. Final results should be known at the latest by 12/07/20.
- I expect the results to be positive/effective enough against both Covid-19 & Type II Diabetes that the share price for $IBRC reaches $.02 and $TSOI reaches $.25.
———————————————————————
OTHER STUDIES involving QuadraMune:
(1) DATE: 08/28/20
Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune™ and Minocycline
August 28, 2020, 6:30 am
Campbell Neurosciences Division Continues its Mission of "Treating Suicide as a Biological Disease"
OCEANSIDE, Calif., Aug. 28, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported filing a patent on new data showing synergy between QuadraMune™ and Minocycline in generating a type of immune cell termed T regulatory cell.
T regulatory cells suppress pathological inflammation, including interleukin-6, which is associated with suicidal ideation, as well as risk of COVID-19 associated death.
QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.
"The recent data supports initiation of clinical trials combining QuadraMune and Minocycline for reduction of suicidal ideations and hopefully preventing suicides" said Kalina O'Connor, Director of the Campbell Neurosciences Division of Therapeutic Solutions International and co-inventor of the patent. "I am thankful to Mr. Dixon and the team at TSOI for having the courage to attack suicide as a biological disease."
Campbell Neurosciences was formed as a Division of the Company to address suicide from an immunological perspective. The company is named after Kathleen Campbell, the mother of Kalina O'Connor, who was a victim of suicide.
"The potent generation of T regulatory cells by the combination of QuadraMune™ and Minocycline suggests that the therapeutic effects of the combination may be long lasting due to the fact that T regulatory cells have a long life in the body and can replicate" said Famela Ramos, Director of Business Development. "The ability of the T regulatory cells generated to suppress interleukin-6 and macrophage activation supports the possible use of this combination for other neurogenerative diseases associated with inflammation."
"By combining quantitative measurements such as the Campbell Score™, with practical interventions such as QuadraMune™ with adjuvants such as Minocycline, we believe that we are primed for initiating a new way of treating suicide based on objective immunology and not speculation" said Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "We thank our Scientific Advisory Board for their leadership in stimulating us to explore this fascinating and underdeveloped area of medicine."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
[1] https://clinicaltrials.gov/ct2/show/NCT04421391
Therapeutic Solutions International, Inc.
ir@tsoimail.com
———————————————————————-
(2) DATE: 08/05/2020
https://www.wfmz.com/news/pr_newswire/pr_newswire_health/therapeutic-solutions-international-reports-reduction-of-inflammation-associated-memory-impairment-by-quadramune-tm-administration/article_70dae53b-5c65-57f3-adce-ac06e0a83968.html
Therapeutic Solutions International Reports Reduction of Inflammation Associated Memory Impairment by QuadraMune(TM) Administration
Animal Data has Potential Implications for Ongoing COVID-19 Prevention Study Company Continues Quest to Dominate Intellectual Property Regarding COVID-19 Associated Pathologies
By Therapeutic Solutions International Aug 5, 2020 Updated Aug 5, 2020
OCEANSIDE, Calif., Aug. 5, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today filing of a patent on new data demonstrating memory-protective effects of QuadraMune™ in an animal model of inflammation associated memory loss.
Animals were treated with QuadraMune™ for 3 days and exposed to lipopolysaccharide, which serves as an inflammatory stimulus. Subsequently, the ability of animals to remember a submerged platform was assessed. In agreement with previously published studies, lipopolysaccharide administration resulted in approximately 57% reduction in memory. Animals which received QuadraMune had restoration of memory activity. Additionally, it was demonstrated that QuadraMune™ reduced the presence of proteins associated with inflammation in the brain, termed cytokines.
"The current data is an extension of our ongoing obsession with identifying mechanisms by which QuadraMune™ works and expanding its potential for other diseases. It is known that conditions such as Alzheimer's Disease, Multiple Sclerosis and Parkinson's Disease are all associated with brain inflammation [1, 2]," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The same cytokines, such as interleukin 6, that we are reducing with QuadraMune™ in the brain, are associated with COVID-19 severity [3]. Studies show that viral infections in general, and especially the SARS-CoV-2 virus, can cause memory impairment. It will be interesting to explore whether QuadraMune™ may have therapeutic effects in this arena."
QuadraMune™ is comprised of green tea extract, pterostilbene, nigella sativa, and sulforaphane. Studies published in the peer-reviewed literature have shown that these ingredients by themselves possess anti-inflammatory [4-7], neuroprotective [8-13], and immune stimulatory properties [14-17].
"It has not escaped us that mental health issues such as dementia and depression are associated with inflammatory cytokines [18, 19]. We are currently investigating the possibility of utilizing QuadraMune™ or similar formulations for psychiatric indications," said Famela Ramos, director of business development and co-inventor on the patent.
"I am very thankful for our scientific advisory board, and our research collaborators who are working tirelessly to advance QuadraMune™ into new indications, as well as identifying mechanisms of action," said Timothy Dixon, President and CEO of the Company. "We plan to continue expanding our collaborations and strengthening our science and portfolio, because at the end of the day, the best marketing is when the science speaks for itself."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com , our public forum where all are welcome is https://board.therapeuticsolutionsint.com/ and all referenced lit may be reviewed here: https://therapeuticsolutionsint.com/news-8-5-2020-refrences/
Therapeutic Solutions International, Inc.
ir@tsoimail.com
———————————————————————-
Therapeutic Solutions International Files Patent on Ability of QuadraMune Ingredient Pterostilbene to Reduce Inflammation while Stimulating Brain Protective Biological Pathways
Published: July 28, 2020 at 9:45 a.m. ET
OCEANSIDE, Calif., July 28, 2020 /PRNewswire via COMTEX/ -- OCEANSIDE, Calif., July 28, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported new data demonstrating that the blueberry derived compound pterostilbene possesses numerous brain protective and potentially brain regenerative activities. Pterostilbene is one of four ingredients which comprise QuadraMune™, a nutraceutical being developed by the Company which is currently in a clinical trial for prevention of COVID-19. Information on the clinical trial can be found on the Government Clinical Trials website https://clinicaltrials.gov/ct2/show/NCT04421391.
"These new data confirm previous findings published on pterostilbene and also reveal novel therapeutic properties of this naturally occurring nutrient," said Dr. James Veltmeyer, Chief Medical Officer of the Company and Voted Top Doctor of San Diego. "By continually investigating mechanisms of action of our products, our ambition is to ensure we have support of the top medical and scientific leaders. In my opinion, many times, it does not matter how good your product is, what matters is that you have scientific basis for why it works. This is especially important in the current age of molecular medicine."
Advertisement
The data disclosed by the Company indicates:
a) pterostilbene suppresses inflammatory cytokines TNF-alpha, IL-1 beta and IL-6;
b) pterostilbene inhibits death of neurons caused by inflammatory mediators;
c) pterostilbene stimulates production of regenerative factors from cells in the brain such as BDNF, NGF, FGF-1, and FGF-2; and
d) pterostilbene allows/enhances proliferation of endogenous brain stem cells.
"The importance of possessing a deep scientific understanding of your product can be seen in the example of nutraceuticals which ended up obtaining regulatory clearance as drugs," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "For example, Lovaza and Vascepa are both fish oil based products which have been developed scientifically and FDA approved through clinical trials. Lovaza, which is sold by GSK, had sales of approximately 1 billion per year and is used for reduction of triglycerides.1 Vascepa, sold by Amarin, had sales in 2019 of 410 million and is used to prevent heart attacks.2 We believe that similar developmental pathways may be possible with several of our existing products."
The Company is currently pursuing FDA clearance for its cell therapy produce StemVacs, for which an IND number was previously granted. The Company's in-licensed stem cell, the JadiCell has FDA clearance for other indications.
Advertisement
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, our public forum is https://board.therapeuticsolutionsint.com/.
1 http://www.pmlive.com/pharma_news/teva_launches_first_generic_of_gsks_lovaza_in_us_559273
2https://www.fool.com/investing/2020/01/07/amarin-reports-preliminary-vascepa-sales-projects.aspx
Therapeutic Solutions International, Inc.
ir@tsoimail.com
View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-files-patent-on-ability-of-quadramune-ingredient-pterostilbene-to-reduce-inflammation-while-stimulating-brain-protective-biological-pathways-301101258.html
SOURCE Therapeutic Solutions International
(#) DATE: 06/04/2020
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-announces-positive-preclinical-and-clinical-evaluation-of-nutritional-supplement-quadramune-designed-to-protect-against-covid-19-301070796.html
Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19
Company Submits Results of Clinical Trial for Publication in Peer-Reviewed Medical Journal
NEWS PROVIDED BY
Therapeutics Solutions International, Inc.
Jun 04, 2020, 09:08 ET
OCEANSIDE, California, June 4, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the submission to an international medical journal the results of pre-clinical and clinical evaluation of QuadraMune™ in 32 healthy volunteers between 18-65 years of age, lacking chronic or active disease.
The study comprised of 4 groups of patients who received QuadraMune™, or placebo. Group 1 was placebo control, Group 2 received 2 capsules per day, group 3 received 4 capsules per day, and group 4 received 8 capsules per day. The trial lasted 7 days. QuadraMune™ was provided by Therapeutic Solutions International.
"To date, there are no FDA cleared means of preventing COVID-19. Despite work being performed at 'Warp-Speed' towards vaccine development, these efforts are still believed to be months if not years away," said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International and "Top Doctor" of San Diego in 2012, 2014, 2016, 2017, and 2019. "We aimed to perform a series of experiments to assess preclinical and pilot clinical feasibility of QuadraMune™ to address the issue of immune stimulation while inhibiting inflammation. The current data strongly supports that the combination of natural ingredients in QuadraMune™ possesses a synergistic effect at suppressing key components of 'Cytokine Storm,' namely interleukin-6 and TNF-alpha. If studies continue to support these conclusions, future use of QuadraMune™ in conditions such as cancer inflammation and rheumatoid arthritis will be considered."
The cytokine interleukin-6 is considered a cornerstone of the inflammatory response. Suppression of interleukin-6 for pathological inflammation, such as in rheumatoid arthritis, is the basis of the drug Actemra (Tocilizumab). Manufactured by Roche, this drug had sales of $2.4 billion dollars last year.[1]
"In vivo administration of QuadraMune™ was successful in stimulating markers of immunity both at the level of the innate immune response, and adaptive immune responses," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "Many approaches that suppress inflammation also suppress immunity. In order to have a fighting chance, any approach being developed for this condition must induce both the suppression of inflammation and the activation of immunity. These early data support this statement."
The Company plans to expand clinical trials to patients suffering from COVID-19 and/or individuals at risk of COVID-19. A pre-publication copy, of the submitted manuscript, is available by following this link: https://therapeuticsolutionsint.com/CV/JTRM-D-20-01014.pdf.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on QuadraMune™ visit www.areyoucovidmune.com/covidmune/.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
1. https://www.fiercepharma.com/pharma-asia/china-turns-roche-arthritis-drug-actemra-against-covid-19-new-treatment-guidelines
Nutraceutical Product Appears to Stimulate Natural Killer Cell Arm of Immune System
Contact:
Timothy Dixon
Therapeutic Solutions International, Inc.
ir@tsoimail.com
+1-(760)-295-7208
SOURCE Therapeutics Solutions International, Inc.
Related Links
https://therapeuticsolutionsint.com
Also from this source
Therapeutic Solutions International Universal Donor Immunotherapy ...
Therapeutic Solutions International Announces Intention to Use...
Reverse Split coming, a very big one. Dumped 15.33 million shares. Good luck to everyone who decides to stay in this. Any time I hear huge reverse split coming I think one thing and that is “if the company isn’t good enough without the Reverse Split, they’ll NEVER be good enough with it. Good luck. Don’t get stuck holding the bag.
Everyone just sit back and relax. This stock isn’t moving for awhile. This company has been hammered by Covid-19 and it’s going to take them 3-6 months before any progress is made. I doubt they even file anything until around the new year. Here’s a copy of the sec.gov Form 8k document that was filed to extend their original due date for the 10Q that still hasn’t come out (8/14/20, 9/28/20, still waiting...). As long as the company doesn’t do a reverse split or file bankruptcy and liquidate our shares, the stock will bounce back, share price will thrive, and anyone holding millions of shares will be very happy. Just stack them @ $.0001 or even .0002 (if you don’t care), and sit back and wait for 6 months. Give some love to the other potentially good stocks. This one should go sometime next year when the company bounces back. Until then, we wait.
https://www.sec.gov/Archives/edgar/data/1334589/000139390520000235/plyz_8k.htm
Loading up all the time. I’ve been in this stock since June & it’s getting closer to popping. Sometime around Nov 14th supposedly there will be an earnings report released. Also, chart analysis indicates that this stock is ready to start ticking upwards on or around November 1st. Chart is also 3/4 of the way through making the classic “w” shape, which can indicate a spike is coming. It’ll be completed on Nov 1st.
Right now .0001’s are hard to come by (can take up to 4-5 days for orders to get filled). LS has invested as well as other big investors. This is a gem. Load up while you can, we’ll probably only have 1-2 weeks tops before .0001’s are gone for good.
If this is allowed to run, without the company doing a reverse split, we could all make a lot of money getting in here. Keep loading and keep your fingers crossed that this rockets up.
Any person thinking for a quick payday here is setting themself up for a huge mistake. This is definitely a solid long-term play stock that is eventually going to surpass its $.14 highs from a couple of years ago. This is the best play this company has had in quite awhile, if not ever. Eventually it hits big. For the smart players, load this thing up @ $.0005 because once it goes you won’t see it back down here for a very, very long time, if ever. Load up.